178 related articles for article (PubMed ID: 35840162)
1. Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.
Battaglia NG; Murphy JD; Uccello TP; Hughson A; Gavras NW; Caldon JJ; Gerber SA; Lord EM
J Immunol; 2022 Aug; 209(3):629-640. PubMed ID: 35840162
[TBL] [Abstract][Full Text] [Related]
2. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
[TBL] [Abstract][Full Text] [Related]
3. NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
Salomé B; Sfakianos JP; Ranti D; Daza J; Bieber C; Charap A; Hammer C; Banchereau R; Farkas AM; Ruan DF; Izadmehr S; Geanon D; Kelly G; de Real RM; Lee B; Beaumont KG; Shroff S; Wang YA; Wang YC; Thin TH; Garcia-Barros M; Hegewisch-Solloa E; Mace EM; Wang L; O'Donnell T; Chowell D; Fernandez-Rodriguez R; Skobe M; Taylor N; Kim-Schulze S; Sebra RP; Palmer D; Clancy-Thompson E; Hammond S; Kamphorst AO; Malmberg KJ; Marcenaro E; Romero P; Brody R; Viard M; Yuki Y; Martin M; Carrington M; Mehrazin R; Wiklund P; Mellman I; Mariathasan S; Zhu J; Galsky MD; Bhardwaj N; Horowitz A
Cancer Cell; 2022 Sep; 40(9):1027-1043.e9. PubMed ID: 36099881
[TBL] [Abstract][Full Text] [Related]
4. Qa-1
Zhang X; Sabio E; Krishna C; Ma X; Wang J; Jiang H; Havel JJ; Chan TA
Mol Cancer Res; 2021 Jun; 19(6):1076-1084. PubMed ID: 33674442
[TBL] [Abstract][Full Text] [Related]
5. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
[TBL] [Abstract][Full Text] [Related]
6. The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes.
Lohwasser S; Kubota A; Salcedo M; Lian RH; Takei F
Int Immunol; 2001 Mar; 13(3):321-7. PubMed ID: 11222501
[TBL] [Abstract][Full Text] [Related]
7. NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.
van Montfoort N; Borst L; Korrer MJ; Sluijter M; Marijt KA; Santegoets SJ; van Ham VJ; Ehsan I; Charoentong P; André P; Wagtmann N; Welters MJP; Kim YJ; Piersma SJ; van der Burg SH; van Hall T
Cell; 2018 Dec; 175(7):1744-1755.e15. PubMed ID: 30503208
[TBL] [Abstract][Full Text] [Related]
8. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
9. Natural Killer Group 2A Expressed on Both Peripheral CD3
Yi RT; Niu YH; Liu HL; Zhang TY; Yang YC; Zhang Y; Yin DL; Chen TY; Zhao YR
J Interferon Cytokine Res; 2016 Dec; 36(12):689-697. PubMed ID: 27828717
[TBL] [Abstract][Full Text] [Related]
10. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell Small Molecule Secretome Induces the Immune Checkpoint NKG2A and Dysfunction of Human CD8+ T Cells.
Rodriguez-Garcia GJ; Graves DK; Mirza MB; Idrees K; Kim YJ; Korrer MJ; Rathmell JC
Immunohorizons; 2024 Jun; 8(6):464-477. PubMed ID: 38922288
[TBL] [Abstract][Full Text] [Related]
12. The inhibitory receptor CD94/NKG2A on CD8
Eugène J; Jouand N; Ducoin K; Dansette D; Oger R; Deleine C; Leveque E; Meurette G; Podevin J; Matysiak T; Bennouna J; Bezieau S; Volteau C; Thomas WEA; Chetritt J; Kerdraon O; Fourquier P; Thibaudeau E; Dumont F; Mosnier JF; Toquet C; Jarry A; Gervois N; Bossard C
Mod Pathol; 2020 Mar; 33(3):468-482. PubMed ID: 31409873
[TBL] [Abstract][Full Text] [Related]
13. Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC
Zhang J; Larrocha PS; Zhang B; Wainwright D; Dhar P; Wu JD
J Immunother Cancer; 2019 Aug; 7(1):223. PubMed ID: 31446896
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
[TBL] [Abstract][Full Text] [Related]
15. Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.
Pieper AA; Rakhmilevich AL; Spiegelman DV; Patel RB; Birstler J; Jin WJ; Carlson PM; Charych DH; Hank JA; Erbe AK; Overwijk WW; Morris ZS; Sondel PM
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172518
[TBL] [Abstract][Full Text] [Related]
16. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment.
Aoyama S; Nakagawa R; Nemoto S; Perez-Villarroel P; Mulé JJ; Mailloux AW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34135102
[TBL] [Abstract][Full Text] [Related]
17. Adding Indoximod to Hypofractionated Radiotherapy with Anti-PD-1 Checkpoint Blockade Enhances Early NK and CD8
Watanabe T; Gaedicke S; Guffart E; Firat E; Niedermann G
Clin Cancer Res; 2020 Feb; 26(4):945-956. PubMed ID: 31694834
[TBL] [Abstract][Full Text] [Related]
18. A Single-Domain TCR-like Antibody Selective for the Qa-1
Ghaffari S; Upchurch-Ange K; Gimlin S; Tripathi T; Sluijter M; Middelburg J; van Hall T; Weidanz J
J Immunol; 2022 May; 208(9):2246-2255. PubMed ID: 35418467
[TBL] [Abstract][Full Text] [Related]
19. Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8
Abd Hamid M; Wang RZ; Yao X; Fan P; Li X; Chang XM; Feng Y; Jones S; Maldonado-Perez D; Waugh C; Verrill C; Simmons A; Cerundolo V; McMichael A; Conlon C; Wang X; Peng Y; Dong T
Cancer Immunol Res; 2019 Aug; 7(8):1293-1306. PubMed ID: 31213473
[TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
